INCB-57643 is under clinical development by Incyte and currently in Phase I for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to GlobalData, Phase I drugs for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) have a 93% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how INCB-57643’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
INCB-57643 is under development for the treatment of refractory primary myelofibrosis, post-polycythemia vera myelofibrosis, myeloproliferative disorders, myelodysplastic syndrome and post-essential thrombocythemia myelofibrosis. It is administered orally and targets BET family proteins. It was under development for advanced malignancies such as advanced solid tumor or hematologic malignancy, multiple myeloma, acute myelocytic leukemia and diffuse large B cell lymphoma.
Incyte is a biopharmaceutical company, which discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi. The company’s pipeline portfolio encompasses drugs for the treatment of lung cancer, graft versus host disease, b-cell malignancies, solid tumors, non-small cell lung cancer, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.
For a complete picture of INCB-57643’s drug-specific PTSR and LoA scores, buy the report here.